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SIGNIFICANCE
This retrospective cross-sectional study is aimed at charac-
terizing patients with chronic pruritus and identifying pat-
terns and interactions of factors with pruritus. The seman-
tic map analysis showed clinical categories separated in 
different hubs associated with distinct patterns concerning 
sex, aetiology, laboratory findings and pharmacological 
treatment. Diabetes, diagnosis of cancer and psychiatric 
comorbidities were linked with distinct clinical categories 
of itch. Skin eosinophilia was a common finding of chro-
nic pruritus on both diseased and non-diseased skin. This 
study provides a complex analysis of the characteristics of 
patients with chronic pruritus, as well as basic principles for 
a practical clinical work-up and management.
Chronic pruritus profoundly affects patients’ quality 
of life. The objective of this retrospective cross-sec-
tional study was to characterize patients with chronic 
pruritus and identify patterns, in order to delineate a 
better diagnostic approach. Both semantic connecti-
vity map and classical analysis were applied, linking 
demographic, clinical, laboratory and histopathologi-
cal data with clinical and aetiological categories of 170 
patients with chronic pruritus (median age 72 years, 
58.2% women). The semantic map showed clinical ca-
tegories separated in different hubs associated with 
distinct patterns concerning sex, aetiology, laboratory 
findings, and pharmacological treatment. Diabetes, di-
agnosis of cancer and psychiatric comorbidities were 
linked with certain clinical categories. Skin eosinophi-
lia was a common finding of chronic pruritus, on both 
diseased and non-diseased skin. High frequencies of 
patients with chronic pruritus taking anti-arrhythmics, 
beta-blockers and AT-II receptor antagonists were 
noticed among those with underlying systemic, neu-
rological and psychiatric diseases. This study provides 
a complex analysis of chronic pruritus and thus basic 
principles for a clinical work-up.
Key words: chronic pruritus; classification; semantic map; 
eosino philia.
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Pruritus was defined in 1660 by Samuel Hafenreffer as an unpleasant sensation leading to scratching. Acute 
pruritus has been distinguished from chronic pruritus 
(CP), which is defined as pruritus lasting for 6 weeks or 
more (1, 2). CP has been found more frequently in women 
than men, and its incidence increases with age. Depen-
ding on the severity and chronicity, CP may profoundly 
affect patients’ quality of life (3). In a recent study, CP 
was shown to be as debilitating as chronic pain (4). 
Pruritus may involve either the entire skin (generalized 
pruritus) or only particular areas (localized pruritus). 
The current Clinical Classification of Itch of the Inter-
national Forum for the Study of Itch focuses on clinical 
signs, in particular the presence or absence of primary 
and secondary skin lesions. Thus, 3 clinical categories 
(CC) have been defined: pruritus on diseased (inflamed) 
skin (CC-I), pruritus on non-diseased (non-inflamed) 
skin (CC-II), and pruritus presenting with severe chronic 
secondary scratch lesions, such as prurigo nodularis (CC-
III). Furthermore, underlying conditions causing itch 
have been categorized into 6 categories: dermatological 
diseases (aetiological category (EC)-I); systemic diseases 
including diseases associated with pregnancy and drug-
induced pruritus (EC-II); neurological and psychiatric 
diseases (EC-III, EC-IV); more than one cause of pruritus 
(category “mixed”, EC-V); and underlying disease not 
identified (category “others”, EC-VI) (2).
Data on CP as a common symptom and its epidemio-
logical, clinical and histopathological context remain 
scarce. This study therefore aimed at characterizing pa-
tients referred to a tertiary university centre for evaluation 
of CP by applying the above classification of itch. Based 
on this classification, as well as on demographic, clinical, 
laboratory, and histopathological data, the study sought 
to identify patterns potentially helpful as diagnostic tools 
and to improve the management of patients.
METHODS
Study design
This was a retrospective cross-sectional study including all 
consecutive inpatients with CP as main diagnosis referred to and 
diagnosed at the Department of Dermatology, Inselspital, Uni-
versity Hospital of Bern between January 2010 and December 
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2015. Cases were retrieved by searching the keywords “chronic 
pruritus” and “itch” in the lists of diagnoses of the department’s 
electronic medical report archives. The electronic files of all cases 
were reviewed, and relevant retrospective data were extracted 
systematically using a standardized clinical report form (Table 
SI1). The study was approved by the Ethics Committee of the 
Canton of Bern, Switzerland. General informed consent had 
been obtained from all patients prior to the study. All clinical 
investigations were conducted according to the principles of the 
Declaration of Helsinki.
Collected data
Collected data included demographics, patients’ history, presence 
of comorbidities (such as diabetes mellitus, arterial hypertension, 
hyperlipidaemia, ulcer, chronic liver diseases (CLD), chronic kid-
ney diseases (CKD), cancer and psychiatric condition), previous 
and current treatments, clinical presentation, dermatopathological 
findings, laboratory results, radiological imaging and patch test 
results, where available. In particular, normal and abnormal ranges 
of laboratory parameters were defined according to the criteria 
listed in the footnote to Table SII1.
Based on these data, patients with CP were classified according 
to their clinical picture and history, as well as underlying diseases 
according to the International Forum for the Study of Itch (2). Since 
the number of patients was limited, groups EC-III and IV as well 
as EC-V and VI were merged for statistical purposes. 
Statistical analysis
Data were presented as numbers with percentages, or medians 
with interquartile ranges (IQR) for categorical and continuous 
variables, respectively. Differences in the distribution of factors 
across strata of clinical and aetiological classification of CP were 
assessed by means of Kruskal–Wallis and Pearson’s χ2 tests or 
Fisher’s exact test where required, for continuous and categorical 
variables, respectively. Before starting the study, it was estimated 
that, with 170 patients, the study would be able to detect a mi-
nimum effect size of 0.26 for continuous variables (as measured 
by Cohen’s f) and of 0.27 for categorical variables (as measured 
by Cohen’s w), by considering 4 groups or fewer overall (1-way 
analysis of variance (ANOVA) and Pearson’s χ2 tests, α = 0.05, 
β = 0.20). These correspond to a medium effect size according to 
Cohen’s guidelines (5). All tests were considered significant at p-
value < 0.05. Analyses were performed with SPSS ver. 20 (IBM 
Corp, Armonk, NY, USA).
Semantic map analysis
Associations among variables that were selected based on their 
clinical relevance and statistical significance (i.e. sex, age, duration 
of disease, presence of atopy, cancer occurrence within the last 5 
years, abnormal levels of eosinophils, haemoglobin (Hg), glycated 
haemoglobin (HbA1c), creatinine, thyroid-stimulating hormone 
(TSH), aspartate transaminase (ASAT), alanine transaminase 
(ALAT) and total bilirubin, positivity to serum protein electropho-
resis and/or serum immunofixation, use of angiotensin-converting-
enzyme (ACE) inhibitors, angiotensin (AT)-II antagonists, beta 
blockers, calcium (Ca) antagonists, antidiabetics, diuretics, anti-
lipaemics and tranquilizers, clinical and aetiological classification 
of CP) were analysed by means of a data-mining algorithm that is 
able to compute and display the best connections between each pair 
of variables, taking into account other covariates in the system, as 
described elsewhere (6, 7).
Briefly, multiple logistic regression models were fitted by taking 
each time, sequentially, a variable as the predictor and the other 
as covariates. This process was reiterated until all variables in the 
model were processed. In addition, in order to avoid trivial as-
sociations, correlation among laboratory parameters was removed 
from the process. Finally, a matrix of normalized weights was pro-
duced from the regression coefficients. A mathematical filter, the 
maximum spanning tree (MST) (8), was then applied to the matrix 
of weights and a semantic connectivity map was generated. The 
MST selected positive associations ensuring to have normalized 
correlations in the interval [0, 1]. In addition, in order to avoid 
unstable associations, only connections with a p-value < 0.15 were 
considered by the algorithm. In the map, hubs of variables were 
detected, with straight lines showing the strongest associations, 
while spatial proximity between variables indicating patterns of 
direct correlations. The strength of associations can be interpreted 
as mild, moderate or strong for values < 0.6, 0.6–0.79 and ≥ 0.8, 
respectively (6). The analysis was carried out using MATLAB 
v.9.2 (MathWorks, Natick, MA, USA).
RESULTS
Patient demographics
Over a period of 6 years, 170 patients were hospitalized 
for evaluation of CP. The median duration of CP was 13.5 
months (IQR 5–60 months). The frequency of patients 
with CP among all hospitalized patients in this period 
was 5%. The median age of all patients was 72 years 
(IQR 61–80 years). There was a predominance of fema-
les (58.2%). Based on the clinical presentation, 47.6% 
of all patients with CP had pruritus on diseased skin 
(CC-I). These patients had the following skin diseases: 
eczema, drug reaction, urticaria, bullous pemphigoid, 
psoriasis, scabies, mycosis fungoides, and Sézary syn-
drome. Furthermore, 17.6% of all patients had pruritus 
on non-diseased skin (CC-II) and 34.7% had pruritus 
with chronic scratch lesions (CC-III) (Table I). The 
aetiological classification based on the diagnoses and 
medical reports is listed in Table I.1https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-3405
Table I. Classification of chronic pruritus in 170 patients participating in the study according to clinical and aetiological categories
Clinical category
Aetiological category
I: Dermatological
n (%)a
II: Systemic
n (%)a
III: Neurological
n (%)a
IV: Psychogenic
n (%)a
V: Mixed
n (%)a
VI: Other
n (%)a
Total
n (%)b
I: Pruritus on diseased skin 81 (100.0)   0 (0.0) 0 (0.0) 0 (0.0)   0 (0.0) 0 (0.0) 81 (47.6)
II: Pruritus on non-diseased skin 0 (0.0) 12 (40.0) 1 (3.3) 4 (13.3) 12 (40.0) 1 (3.3) 30 (17.6)
III: Chronic scratch lesions 0 (0.0) 14 (23.7) 1 (1.7) 7 (11.9) 32 (54.2) 5 (8.5) 59 (34.7)
Total 81 (47.6) 26 (15.3) 2 (1.2) 11 (6.5) 44 (25.9) 6 (3.5) 170 (100.0)
aPercentages computed along table rows. bPercentages computed in table columns.
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Semantic map analysis reveals sex-specific chronic 
pruritus patterns 
On the semantic map showing the best associations 
among selected variables, the CC I–III are separated in 
different hubs (Fig. 1). CP associated with diseased skin 
(CC-I) and EC-I is linked to males. CC-II is not only 
associated with the diagnosis of cancer, but also links to 
abnormal bilirubin, ALAT and creatinine blood levels. 
Abnormal bilirubin levels are further linked to male sex, 
elevated HbA1c levels, indicating diabetic disposition 
and respective concomitant therapy in one hub, as well 
as to antihypertension drugs (primarily AT-II receptor 
antagonists) and diuretics. CC-III is associated with 
EC-V–VI as well as EC-III–IV, which is further connec-
ted to female sex, but also to AT-II receptor antagonists. 
Diabetes and cancer are linked to pruritus on non-
diseased skin and chronic scratch lesions 
Comorbidities of patients with CP are reported in Table 
II. Hypertension (60%) was the most common comor-
bidity and equally represented in CC- I, II and III. The 
frequency of diabetes and cancer within the last 5 years 
was highest in patients with CC-II (Table II). Out of 
the patients with cancer diagnosis in the past 5 years, 
13 patients had no active disease and in 5 patients the 
diagnosis of cancer was made by diagnostic work-up 
for CP. When patients were stratified based on aetiolo-
gical causes, a high frequency of CLD was observed in 
EC-II, and in EC-III–IV and EC-V–VI. In CC-II and 
CC-III groups, the frequency of patients with CP with 
psychiatric comorbidities was higher compared with 
Fig. 1. Semantic map showing the best connections among selected variables in the study. The numbers on connecting lines indicate normalized 
correlations (between 0 and 1). The line thickness corresponds to the strength of association (thin line < 0.6; medium line 0.6–0.79; thick line ≥ 0.8). 
Abnorm: abnormal, ACE: angiotensin-converting-enzyme; ALAT: alanine transaminase; ASAT: aspartate transaminase; AT: angiotensin; Ca: calcium; Cat: 
category; Creatin: creatinine; Eosinoph: Electroph: electrophoresis, eosinophils; Etiolog: aetiological; HbA1c: glycated haemoglobin; Hg: haemoglobin; 
Immunofix: immunofixation; Inhibit: inhibitors; TSH: thyroid-stimulating hormone.
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that of CC-I. Psychiatric comorbidities were identified 
in patients of all EC groups, with highest frequencies in 
EC-III–IV and EC-V–VI (Table II). 
Among patients with CP on diseased skin, 51.9% pre-
sented with dry skin and 61.7% with eczematous lesions. 
Thus, papules and plaques were the most commonly 
observed primary skin lesions, and 90.6% of patients 
also had secondary lesions (Table SIII1).
Eosinophil infiltration is a common finding in biopsies 
of patients with chronic pruritus
Light microscopy studies of 105 biopsy specimens 
were performed to either confirm or exclude a specific 
dermatosis that might be responsible for the CP. All 
histopathological slides were assessed by experienced 
dermatopathologists who performed a pattern analysis 
(9). The current study investigated whether the dermato-
pathological findings correlated with CP groups or aetio-
logies. It was notable that the presence of eosinophils in 
the skin was obvious in 72.2% of biopsies from patients 
with CP in CC-I and ≥ 50% in CC-II and III (Table SIV1). 
The most common patterns described were spongiotic 
and eosinophilic patterns in CC-I, spongiotic and unspe-
cific patterns in CC-II, and unspecific pattern in CC-III 
(Table SIV1). As detected by direct immunofluorescence 
microscopy analysis, depositions of IgG, IgM, IgA and/
Table II. Demographics, comorbidities and clinical history of the study population, overall and in strata of clinical and aetiological 
categories of chronic pruritus
Total
n (%)
Clinical category Aetiological category
I: Pruritus 
on diseased 
skin
n (%)
II: Pruritus on 
non-diseased 
skin
n (%)
III: Chronic 
scratch 
lesions
n (%)
p- 
valuea
I: 
Dermato-
logic
n (%)
II: 
Systemic
n (%)
III–IV: 
Neur/Psyc
n (%)
V–VI: 
Mixed/Other
n (%)
p- 
valuea
Sex
  Male 71 (41.8) 43 (53.1) 11 (36.7) 17 (28.8) 0.01 43 (53.1) 12 (46.2) 2 (15.4) 14 (28.0) 0.007
  Female 99 (58.2) 38 (46.9) 19 (63.3) 42 (71.2) 38 (46.9) 14 (53.8) 11 (84.6) 36 (72.0)
Age, years, median (IQR) 72 (61–80) 71 (61–79) 71.5 (52–84) 75 (62–80) 0.82 71 (61–79) 78 (70–84) 64 (51–75) 73.5 (58–78) 0.11
Atopy
  No 139 (81.8) 63 (77.8) 28 (93.3) 48 (81.4) 0.17 63 (77.8) 25 (96.2) 13 (100.0) 38 (76.0) 0.03
  Yes 31 (18.2) 18 (22.2) 2 (6.7) 11 (18.6) 18 (22.2) 1 (3.8) 0 (0.0) 12 (24.0)
Duration, months, median (IQR) 13.5 (5.5–58.5) 15 (6–57) 14 (5–24) 12 (6–72) 0.60 15 (6–57) 13 (6–36) 14 (3–72) 12 (5–72) 0.88
Primary skin disease
  No 89 (52.4) 0 (0.0) 30 (100.0) 59 (100.0) – 0 (0.0) 26 (100.0) 13 (100.0) 50 (100.0) –
  Yes 81 (47.6) 81 (100.0) 0 (0.0) 0 (0.0) 81 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
Eczema
  No 120 (70.6) 31 (38.3) 30 (100.0) 59 (100.0) – 31 (38.3) 26 (100.0) 13 (100.0) 50 (100.0) –
  Yes 50 (29.4) 50 (61.7) 0 (0.0) 0 (0.0) 50 (61.7) 0 (0.0) 0 (0.0) 0 (0.0)
Dry skin
  No 128 (75.3) 39 (48.1) 30 (100.0) 59 (100.0) – 39 (48.1) 26 (100.0) 13 (100.0) 50 (100.0) –
  Yes 42 (24.7) 42 (51.9) 0 (0.0) 0 (0.0) 42 (51.9) 0 (0.0) 0 (0.0) 0 (0.0)
Urticaria
  No 164 (96.5) 75 (92.6) 30 (100.0) 59 (100.0) – 75 (92.6) 26 (100.0) 13 (100.0) 50 (100.0) –
  Yes 6 (3.5) 6 (7.4) 0 (0.0) 0 (0.0) 6 (7.4) 0 (0.0) 0 (0.0) 0 (0.0)
Other skin diseases
  No 151 (88.8) 62 (76.5) 30 (100.0) 59 (100.0) – 62 (76.5) 26 (100.0) 13 (100.0) 50 (100.0) –
  Yes 19 (11.2) 19 (23.5) 0 (0.0) 0 (0.0) 19 (23.5) 0 (0.0) 0 (0.0) 0 (0.0)
Diabetes mellitus
  No 119 (70.0) 59 (72.8) 15 (50.0) 45 (76.3) 0.003 59 (72.8) 13 (50.0) 10 (76.9) 37 (74.0) 0.11
  Yes 51 (30.0) 22 (27.2) 15 (50.0) 14 (23.7) 22 (27.2) 13 (50.0) 3 (23.1) 13 (26.0)
Hypertension
  No 68 (40.0) 31 (38.3) 11 (36.7) 26 (44.1) 0.72 31 (38.3) 8 (30.8) 5 (38.5) 24 (48.0) 0.50
  Yes 102 (60.0) 50 (61.7) 19 (63.3) 33 (55.9) 50 (61.7) 18 (69.2) 8 (61.5) 26 (52.0)
Hyperlipidaemia
  No 118 (69.4) 57 (70.4) 17 (56.7) 44 (74.6) 0.21 57 (70.4) 17 (65.4) 8 (61.5) 36 (72.0) 0.86
  Yes 52 (30.6) 24 (29.6) 13 (43.3) 15 (25.4) 24 (29.6) 9 (34.6) 5 (38.5) 14 (28.0)
Ulcer
  No 165 (97.1) 80 (98.8) 29 (96.7) 56 (94.9) 0.33 80 (98.8) 25 (96.2) 13 (100.0) 47 (94.0) 0.35
  Yes 5 (2.9) 1 (1.2) 1 (3.3) 3 (5.1) 1 (1.2) 1 (3.8) 0 (0.0) 3 (6.0)
Chronic liver disease
  No 148 (87.1) 75 (92.6) 24 (80.0) 49 (83.1) 0.11 75 (92.6) 18 (69.2) 11 (84.6) 44 (88.0) 0.02
  Yes 22 (12.9) 6 (7.4) 6 (20.0) 10 (16.9) 6 (7.4) 8 (30.8) 2 (15.4) 6 (12.0)
Chronic kidney disease
  No 124 (72.9) 61 (75.3) 21 (70.0) 42 (71.2) 0.80 61 (75.3) 15 (57.7) 11 (84.6) 37 (74.0) 0.24
  Yes 46 (27.1) 20 (24.7) 9 (30.0) 17 (28.8) 20 (24.7) 11 (42.3) 2 (15.4) 13 (26.0)
Cancerb
  No 152 (89.4) 75 (92.6) 23 (76.7) 54 (91.5) 0.04 75 (92.6) 22 (84.6) 11 (84.6) 44 (88.0) 0.46
  Yes 18 (10.6) 6 (7.4) 7 (23.3) 5 (8.5) 6 (7.4) 4 (15.4) 2 (15.4) 6 (12.0)
Psychiatric condition
  No 106 (62.4) 63 (77.8) 15 (50.0) 28 (47.5) < 0.001 63 (77.8) 17 (65.4) 5 (38.5) 21 (42.0) < 0.001
  Yes 64 (37.6) 18 (22.2) 15 (50.0) 31 (52.5) 18 (22.2) 9 (34.6) 8 (61.5) 29 (58.0)
aχ2 test, or Fisher’s exact test where required, and Kruskal–Wallis test were used for nominal and continuous variables, respectively. bIn the last 5 years.
IQR: interquartile range.
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or complement C3 were observed in samples obtained 
from all groups with > 60% in CC-I and III (Table SIV1). 
Nevertheless, the rate of specific findings of direct im-
munofluorescence studies was very low. In fact, bullous 
pemphigoid was diagnosed in only 3 cases in patients 
with CP, based on characteristic immunopathological 
findings and clinical, histological and/or immunosero-
logical criteria. 
Blood eosinophil numbers, creatinine, and HbA1c 
levels show associations with chronic pruritus groups
A panel of laboratory parameters was then analysed. In 
CC-I and EC-I, the blood eosinophil levels were the high-
est (Table SV1). Correspondingly, the relative number of 
patients with elevated blood eosinophil levels was high-
est in CC-I (Table SII1). It is notable that, in patients with 
CP categorized as EC-II, creatinine levels were increased 
compared with all other EC groups, while HbA1c levels 
were highest in CC-II (Table SV1). Significant differences 
in the frequency of patients with pathological laboratory 
results were found for urea, with the highest rate in EC-II. 
Infections were detected in 10/73 (12%), 4/81 (4.7%) and 
1/78 (1.3%) of patients tested for hepatitis virus B and C, 
and HIV, respectively (Table SVI1). In 32 patients with 
CP with suspected contact allergy, epicutaneous patch 
testing was performed that revealed at least one positive 
reaction in 13 patients (40.6%) (Table SVII1).
Chronic pruritus and exposure to pharmacological 
therapies
It was further assessed whether CP was linked to conco-
mitant medication in our patient cohort. No association 
was observed between clinical classification of CP and 
selected drug groups. When EC groups were analysed, 
a higher frequency of patients taking anti-arrhythmics, 
beta-blockers and AT-II antagonists was noticed in the 
EC-II and EC-III–IV groups (Table SVIII1).
Whether and how CP and underlying diseases were 
treated was subsequently investigated. Before hospita-
lization, 76.5% of patients with CP applied a topical th-
erapy (Table SIX1). Notably, in one-third of the patients, 
CP and associated skin lesions were treated with systemic 
drugs, such as methotrexate, cyclosporine, retinoids and 
systemic corticosteroids. Systemic treatment was more 
frequently used in patients of CC-I compared with CC-
II and III (p = 0.005). Oral antihistamines were used in 
31.8% of patients with CP. Phototherapy was used in 
21.2% of all patients with CP, mainly in those of CC-I 
and CC-II.
DISCUSSION
This study provides a comprehensive and detailed cha-
racterization of patients with CP referred to a tertiary 
university centre, by applying the criteria of CP classifi-
cation using both semantic map and conventional statis-
tical analyses. The semantic map, which shows the best 
associations between variables, clearly demonstrates an 
allocation of classification criteria and associated clinical 
and diagnostic variables in 5 distinct areas: 
1. CC-I, EC-I; 
2. CC-II, EC-II, abnormal liver/kidney parameters, 
history of cancer; 
3. CC-III, EC-III–IV, EC-V–VI and females; 
4. diabetes, antidiabetic therapy, and 
5. anti-hypertensives and diuretics. 
While hubs 1–3 show a direct link to the clinical 
presentation, hubs 4 and 5 largely lack such correlation.
A striking finding on the semantic map was the sex dif-
ference, which could be confirmed by classical statistical 
analysis. Females with CP more frequently presented 
with chronic scratch lesions and had concomitant neu-
rological or psychiatric diseases, while CP on diseased 
skin predominated in males. These observations are in 
agreement with previous reports (10, 11). Sex differences 
in the perception of CP and its burden on quality of life 
have been reported. Following intracutaneous histamine 
challenge in patients with CP, females report more severe 
pruritus than males, despite the fact that the males have 
a larger wheal size (12). In females, CP affects quality 
of life more strongly than in males (10, 13).
In the cohort in the current study, CP owing to syste-
mic diseases (EC-II), in particular chronic liver diseases, 
chronic kidney diseases, diabetes and diagnosis of cancer 
in the last 5 years, was common and mainly linked to 
primarily normal, non-inflamed skin (CC-II), as shown 
on the semantic map and by classical statistical analyses. 
It has been reported that, in patients with chronic liver di-
seases, over 40% have pruritus (14, 15). A viral infection 
seems to represent the most common cause of chronic 
cholestatic pruritus (16). In patients with chronic kidney 
disease, uraemic pruritus has been associated mainly 
with haemodialysis (17). In haemodialysis and in renal 
transplant patients CP is found in 62% and 32% of cases, 
respectively (18). Diabetes as comorbidity significantly 
appears to increase the risk of CP in geriatric patients 
in whom the prevalence of CP was 25% in one study 
(19). In elderly patients with diabetes mellitus, pruritus 
is thought to constitute the most common cutaneous 
symptom (20). Population-based studies have revealed 
an increased risk of malignancies, in particular haema-
tological and bile duct malignancies, in patients with 
pruritus compared with those without pruritus (21–23). 
CP associated with malignancies presents on primarily 
non-inflamed skin with or without secondary scratch 
lesions (24). Nevertheless, there is increasing evidence 
that despite the different underlying clinical systemic 
diseases in patients with CP, the pathogenesis of itch is 
rather uniform, involving predominantly the IL-31/IL-31 
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receptor axis (25–28). Notably, we observed both tissue 
and blood eosinophilia frequently associated with CP. 
Eosinophils that are attracted and activated by IL-31, are 
also capable of releasing IL-31 and may thus contribute 
to itch, as in bullous pemphigoid (29, 30).
Pruritus is critically modulated by the psychological 
and emotional state of the patient, which can either 
cause or maintain pruritic symptoms (31). Among pa-
tients with CP referred by a dermatologist to a tertiary 
centre, 77.1% had at least 1 psychiatric/psychosomatic 
comorbidity (32). In our cohort, CP with severe chronic 
secondary scratch lesions (CC-III) was found to be as-
sociated with neurological/psychiatric diseases (EC-III/
IV) and mixed/other diseases (EC-V/VI), as well as with 
female sex. This observation is in line with a previous 
report (10). Interestingly, pruritus on the head/neck area 
is most frequently reported by patients with CP who 
have neurological/psychiatric diseases. Notably, the link 
between hepatitis B and C viral infections and EC-III/
IV and EC-V/VI could be traced back to chronic drug 
and alcohol abuse with or without concomitant internal 
diseases in these patients.
The association of CP with pharmacological treatments 
has been assumed, in particularly in elderly patients 
(33). However, in 1 investigation focusing on a geriatric 
population, no correlation between medication use and 
pruritus was found (19). A French case-control study 
reported a significant association between intake of cal-
cium channel blockers and chronic eczematous eruption 
in elderly patients (34). In line with these findings, our 
study cohort showed a correlation of CP with hyperten-
sion and intake of anti-hypertensives, as well as diabetes 
and use of anti-diabetic drugs. Further investigation is 
needed to determine whether the association of AT II 
antagonist use with neurological/psychiatric diseases or 
abnormal blood bilirubin levels in patients with CP is 
clinically relevant or causative. 
Study limitations
Limitations of this study include that it was a single-
centre study, and that only patients hospitalized in a 
dermatological department have been analysed, while 
patients with CP cared for by other specialities were not 
included. 
Conclusion
This study reveals a number of interesting associations 
between clinical presentations and aetiology, including 
pharmacological treatment, as well as sex differences 
in patients with CP by applying semantic map and clas-
sical statistical analyses. It should be noted that, despite 
these statistical correlations, there might be overlapping 
conditions in clinical practice. Therefore, the diagnostic 
work-up should consider: (i) the clinical presentation; (ii) 
a comprehensive patient history with focus on comorbi-
dities and drug therapy; (iii) light microscopy and direct 
immunofluorescence studies of skin biopsy specimens, 
laboratory and imaging examinations (according to (ii)); 
and (iv) an evaluation on the psychological/psychosoma-
tic status of patients with CP.
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